---
document_datetime: 2025-10-27 15:23:22
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/adtralza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: adtralza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7946152
conversion_datetime: 2025-12-19 11:17:05.729885
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Adtralza

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB / EMA/VR/0000294330 | B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.c Implementation of a | 18/09/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | change for a biological/immunological medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000254976 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.8 and 5.1 of the SmPC in order to update clinical efficacy and safety information based on the final clinical trial report of the open-label extension PASS study LP0162-1337 (ECZTEND), listed as a category 3 study in the RMP. This is a phase 3 open-label, single-arm, multi-centre, long- term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with moderate-to-severe atopic dermatitis who participated in previous tralokinumab clinical trials. The RMP has been updated to version 3.0. In addition, the MAH took the opportunity to update the PI according to the updated EU Excipient guideline to include a warning regarding polysorbate as well as to include minor editorial changes and to update the list of local representatives in the Package Leaflet. | 04/09/2025 | SmPC, Labelling and PL | The long-term efficacy of tralokinumab was further assessed in an open-label extension study (ECZTEND) in adults (1545 subjects) and in adolescents 12 years and older (127 subjects) with moderate-to-severe AD who had participated for up to 1 year in previous tralokinumab studies. For the total population, the median and maximum exposure time in ECZTEND was 2.6 and 5.1 years; for adolescent subjects, the median and maximum exposure time in ECZTEND was 1.8 and 2.2 years. Efficacy data from ECZTEND indicate that the clinical benefit achieved during initial treatment and maintenance treatment is sustained during long- term treatment with 300 mg of tralokinumab every two weeks (Q2W) and optional TCS as needed. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000244619   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted   | 03/07/2025   | Annex II    |             |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------|-------------|
| Variation type IB / EMA/VR/0000265489   | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                      | 27/05/2025   | SmPC and PL |             |
| Variation type IB / EMA/VR/0000265037   | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                                                                  | 16/05/2025   | SmPC        |             |
| PSUR / EMA/PSUR/0000257863              | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |              |             | Maintenance |